Guidance |
Implied guidance |
|
| Sales growth in local currencies | +4% to +8% |
-6% to -8% |
| Adjusted EBITA growth* in local currencies | +20% to 30% |
~0% |
* EBITA guidance excludes restructuring costs in both FY 2019/20 and FY 2020/21, damages awarded in patent infringement lawsuit to Advanced Bionics in FY 2020/21 as well as one-time costs related to the voluntary field corrective action in the CI segment in FY 2019/20
For the second half of the financial year 2020/21, the Group expects revenue growth of 4%-8% and an increase of the adjusted EBITA in the range of 20%-30% compared with the prior year period, both at constant exchange rates.
For financial year 2020/21, this implies a sales decline of 6%-8% and the adjusted EBITA to be at around prior year levels, both at constant exchange rates.
The outlook considers a limited temporary impact from the recent rise in infection rates and re-tightening of lockdown restrictions in several markets. Beyond the headwinds from the momentary reacceleration of the pandemic, the Group expects a continued gradual market recovery.
As a consequence of the strengthening of the Swiss franc and reflecting mid-November exchange rates, Sonova anticipates reported sales growth in Swiss francs to be reduced by around 5 percentage points and the adjusted EBITA growth in Swiss francs to be negatively affected by around 10 percentage points in financial year 2020/21.